BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 14, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SCH 900105: Phase II started

Aveo began an open-label, dose-escalation Phase II trial to evaluate Iressa gefitinib with or without intravenous SCH 099105. The start triggers an $8.5...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >